Alzheimer's disease (AD) is a progressive neurodegenerative disease that is difficult to treat. Extracellular amyloid is the principal pathological criterion for the diagnosis of AD. Amyloid β (Aβ) interacts with various receptor molecules on the plasma membrane and mediates a series of signaling pathways that play a vital role in the occurrence and development of AD. Research on receptors that interact with Aβ is currently ongoing. Overall, there are no effective medications to treat AD. In this review, we first discuss the importance of Aβ in the pathogenesis of AD, then summarize the latest progress of Aβ-related targets and compounds. Finally, we put forward the challenges and opportunities in the development of effective AD therapies.

中文翻译：

---

调节β-淀粉样蛋白治疗阿尔茨海默病：治疗策略和生物活性化合物的研究进展

阿尔茨海默病 (AD) 是一种难以治疗的进行性神经退行性疾病。细胞外淀粉样蛋白是诊断 AD 的主要病理学标准。β淀粉样蛋白（Aβ）与质膜上的各种受体分子相互作用，介导一系列信号通路，在AD的发生、发展中起着至关重要的作用。目前正在进行与 Aβ 相互作用的受体的研究。总的来说，没有治疗 AD 的有效药物。在这篇综述中，我们首先讨论了 Aβ 在 AD 发病机制中的重要性，然后总结了 Aβ 相关靶点和化合物的最新进展。最后，我们提出了开发有效的 AD 疗法的挑战和机遇。